In Vitro Activity of Ceftazidime-Avibactam against Isolates in a Phase 3 Open-Label Clinical Trial for Complicated Intra-Abdominal and Urinary Tract Infections Caused by Ceftazidime-Nonsusceptible Gram-Negative Pathogens

被引：23
|
作者：
Stone, Gregory G. [1 ]
Bradford, Patricia A. [1 ]
Newell, Paul [2 ]
Wardman, Angela [2 ]
机构：
[1] AstraZeneca, Waltham, MA 02451 USA
[2] AstraZeneca, Alderley Pk, England
来源：
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 2017年 / 61卷 / 02期
关键词：
ceftazidime nonsusceptible; ceftazidime-avibactam; in vitro activity; BETA-LACTAMASE INHIBITOR; COMBINATION; NXL104;
D O I：
10.1128/AAC.01820-16
中图分类号：
Q93 [微生物学];
学科分类号：
071005 ; 100705 ;
摘要：
The in vitro activity of ceftazidime-avibactam was evaluated against 341 Gram-negative isolates from 333 patients in a randomized, phase 3 clinical trial of patients with complicated urinary tract or intra-abdominal infections caused by ceftazidime-nonsusceptible pathogens (NCT01644643). Ceftazidime-avibactam MIC90 values against Enterobacteriaceae and Pseudomonas aeruginosa (including several class B or D enzyme producers that avibactam does not inhibit) were 1 and 64 mu g/ml, respectively. Overall, the ceftazidime-avibactam activity against ceftazidime-nonsusceptible isolates was comparable to the activity of ceftazidime-avibactam previously reported against ceftazidime-susceptible isolates.
引用
收藏
页数：6
相关论文
共 35 条
  • [1] In Vitro Activity of Ceftazidime-Avibactam against Isolates from Patients in a Phase 3 Clinical Trial for Treatment of Complicated Intra-abdominal Infections
    Stone, Gregory G.
    Newell, Paul
    Bradford, Patricia A.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2018, 62 (07)
  • [2] Ceftazidime-avibactam for the treatment of complicated urinary tract infections and complicated intra-abdominal infections
    Mawal, Yogesh
    Critchley, Ian A.
    Riccobene, Todd A.
    Talley, Angela K.
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2015, 8 (06) : 691 - 707
  • [3] Focus on ceftazidime-avibactam for optimizing outcomes in complicated intra-abdominal and urinary tract infections
    Nicolau, David P.
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2015, 24 (09) : 1261 - 1273
  • [4] In vitro activity of ceftazidime-avibactam against Gram-negative strains in patients with complicated urinary tract infection and complicated intra-abdominal infection in Colombia 2014-2018
    Lemos-Luengas, Elkin, V
    Renteria-Valoyes, Sixta
    Cardenas-Isaza, Paola
    Ramos-Castaneda, Jorge A.
    BRAZILIAN JOURNAL OF INFECTIOUS DISEASES, 2022, 26 (03):
  • [5] In vitro activity of ceftazidime/avibactam against urinary isolates from patients in a Phase 3 clinical trial programme for the treatment of complicated urinary tract infections
    Stone, Gregory G.
    Bradford, Patricia A.
    Yates, Katrina
    Newell, Paul
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2017, 72 (05) : 1396 - 1399
  • [6] Dose Selection and Validation for Ceftazidime-Avibactam in Adults with Complicated Intra-abdominal Infections, Complicated Urinary Tract Infections, and Nosocomial Pneumonia
    Das, Shampa
    Li, Jianguo
    Riccobene, Todd
    Carrothers, Timothy J.
    Newell, Paul
    Melnick, David
    Critchley, Ian A.
    Stone, Gregory G.
    Nichols, Wright W.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2019, 63 (04)
  • [7] Efficacy and safety of ceftazidime-avibactam in combination with metronidazole in Japanese patients with complicated intra-abdominal infection: A phase 3, multicentre, open-label study
    Mikamo, Hiroshige
    Nakazuru, Yoshiomi
    Tabuchi, Riko
    Suzuki, Misaki
    Nagashima, Masahito
    Tawadrous, Margaret
    Wible, Michele
    Ohta, Makoto
    JOURNAL OF INFECTION AND CHEMOTHERAPY, 2025, 31 (03)
  • [8] In Vitro Activity of Ceftazidime-Avibactam against 338 Molecularly Characterized Gentamicin-Nonsusceptible Gram-Negative Clinical Isolates Obtained from Patients in Canadian Hospitals
    Denisuik, Andrew J.
    Karlowsky, James A.
    Denisuik, Tyler
    Nichols, Wright W.
    Keating, Thomas A.
    Adam, Heather J.
    Baxter, Melanie
    Walkty, Andrew
    Zhanel, George G.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2015, 59 (06) : 3623 - 3626
  • [9] Molecular β-Lactamase Characterization of Aerobic Gram-Negative Pathogens Recovered from Patients Enrolled in the Ceftazidime-Avibactam Phase 3 Trials for Complicated Intra-abdominal Infections, with Efficacies Analyzed against Susceptible and Resistant Subsets
    Mendes, Rodrigo E.
    Castanheira, Mariana
    Woosley, Leah N.
    Stone, Gregory G.
    Bradford, Patricia A.
    Flamm, Robert K.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2017, 61 (06)
  • [10] Ceftazidime/avibactam activity tested against Gram-negative bacteria isolated from bloodstream, pneumonia, intra-abdominal and urinary tract infections in US medical centres (2012)
    Flamm, Robert K.
    Farrell, David J.
    Sader, Helio S.
    Jones, Ronald N.
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2014, 69 (06) : 1589 - 1598
1234